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Proteomics and bioinformatics are a useful combined technology for the characterization
of protein expression level and modulation associated with the response to a drug and
with its mechanism of action. The folate pathway represents an important target in
the anticancer drugs therapy. In the present study, a discovery proteomics approach
was applied to tissue samples collected from ovarian cancer patients who relapsed
after the first-line carboplatin-based chemotherapy and were treated with pemetrexed
(PMX), a known folate pathway targeting drug. The aim of the work is to identify the
proteomic profile that can be associated to the response to the PMX treatment in
pre-treatement tissue. Statistical metrics of the experimental Mass Spectrometry (MS)
data were combined with a knowledge-based approach that included bioinformatics
and a literature review through ProteinQuestTM tool, to design a protein set of reference
(PSR). The PSR provides feedback for the consistency of MS proteomic data because
it includes known validated proteins. A panel of 24 proteins with levels that were
significantly different in pre-treatment samples of patients who responded to the therapy
vs. the non-responder ones, was identified. The differences of the identified proteins
were explained for the patients with different outcomes and the known PMX targets
were further validated. The protein panel herein identified is ready for further validation in
retrospective clinical trials using a targeted proteomic approach. This study may have a
general relevant impact on biomarker application for cancer patients therapy selection.
Keywords: pemetrexed, folate pathway, drug resistance, ovarian cancer, proteomics, mass spectrometry,
bioinformatics
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INTRODUCTION
The folate pathway is an important biochemical target for
anti-cancer drugs and overall more than 1,500 clinical trials
are currently running (WWW.clinicaltrials.gov); therefore it
represents an active wide field of study today (Wilson et al., 2014;
Taddia et al., 2015).
After first line treatment of ovarian cancer (OC) patients
with platinum drugs, drug resistance occurs rapidly inducing the
overexpression of folate-dependent proteins such as thymidylate
synthase (TS, TYSY) (Ozasa et al., 2010), dihydrofolate reductase
(DHFR, DYR), the trifunctional purine biosynthetic protein
adenosine-3 (GART, PUR2) and other enzymes involved in
cell replication. Drugs directed against TYSY and the folate
metabolism are being investigated as potential second-/third-
line therapies for platinum drug-resistant OC. Among them
pemetrexed (PMX, AlimtaTM) has been proposed with the
rationale that it can target the mentioned proteins, thus blocking
cancer cell replication and death.
PMX is already in use in colon and pancreatic cancer, as well as
in mesothelioma patients sensitive to TS targeting drugs (https://
www.drugbank.ca/), and it was proposed for use in a clinical
phase II trial for the treatment of resistant OC (Vergote et al.,
2009). A recent review (Egloff and Jatoi, 2014) examined patients
withOCwhowere treated with PMX in a non-clinical trial setting
in Germany; PMX demonstrated to improve the progression
free-survival in a variable manner. The proper selection of the
sub-population that could respond to the proposed therapy could
improve the outcome, if suitable biomarkers to predict PMX
response can be identified.
In our previous studies, using a combination of bioinformatics
and MS proteomics we were able to show, in ovarian cancer
cells sensitive and resistant to cis-platinum, that a new class of
peptidic TS inhibitors induced a proteomic modulation pattern,
when targeting TS, different with respect to other classical
inhibitors, since they behave as protein-protein interaction
inhibitors (Genovese et al., 2014). We identified a protein
set that is specifically modulated when peptides are delivered
to the cancer cells. The results of our study on the cancer
cell models suggest that proteomics and bioinformatics are
a useful combined technology for the characterization of TS
inhibitors induced protein modulation and that this modulation
is associated with their mechanism of action. This suggests the
potential role of the proteomics and bioinformatics technologies
applied to the study of the effect induced by a TS inhibitor on
cancer cells. Therefore, the same technology can be applied to
study human cancer tissues to study anti-folate drugs behavior
in human tissue.
In the present study we applied a previously developed
approach (Genovese et al., 2014) to analyze tissue samples taken
from patients affected by ovarian cancer, after failure of platinum
drug and before second line therapy with PMX. We wanted to
explore if a specific protein expression pattern exists in pre-
treatment samples from patients who responded to the PMX
therapy with respect to the ones who did not respond, and if the
specific pattern can be explained in relation to the thymidylate
synthase cellular role. We applied a label free MS proteomic
analysis combined with bioinformatics (Figure 1A) and adopted
the concept of protein set of references (PSR) to drive the
selection and panel identification process (Figure 1B).
MATERIALS AND METHODS
Experimental Design and Statistical
Rationale
The proteomic study is based on tissue samples taken from
retrospective study aimed to explore and identify a protein
panel that is associated with the response to PMX therapy
based on the analysis of pre-treatment ovarian biopsies. OC
biopsies are collected from women with high-grade serous
ovarian carcinoma, who were subjected, after surgery reduction,
to homogenous first line chemotherapy consisting in carboplatin
and paclitaxel, to variable second/third lines chemotherapy
with or including PMX. During the collaboration within the
EUTROC initiative we have received a total of 52 tissue samples
from the TOC bank (https://forschungsberichte.charite.de/FOB_
2010-2011/english/PJ/PJ49331.html; for the institutional Ethics
Committee approval reference to TOC). We applied the sample
selection protocol reported below and we could only select
three samples that were further analyzed. A proteomic study
was implemented with a two steps experiment. The first
step was the design of a PSR that is compiled through
literature-based analysis focusing on PMX experimentally
detected proteins involved in the mechanism of action or
relevant marker of its activity (Figure 1A). It was additionally
enriched with experimental proteins modulated in OC cell
lines when treated with PMX performed during a previous
work (Taddia, 2015). Identification of a protein subset that
characterizes the activity of folate metabolism targeted Ph.D.
thesis. University of Modena and Reggio Emilia (unpublished
data). The second step was the label-free MS proteomic study
of the tissues in which a stepwise protein selection was
performed following the criteria presented below (Figure 1B).
Monitoring of the stepwise selection consistency is performed
by comparison with the PSR. The final panel was then obtained
and three proteins were further validated using a western-blot
analysis.
Sample Selection
All the 52 tissue samples were histologically analyzed. Only
non-fibrous OC tissue samples that showed a percentage of
cancer cells >80% were further considered. Uniformity of
the cancer cells percentage among biopsies is necessary to
perform a differential analysis of the whole proteomes. We
decided to consider only biopsies from patients who were
subjected, before surgery reduction, to homogenous first line
chemotherapy consisting in carboplatin and paclitaxel and,
eventually, to a second line chemotherapy, and after surgery
reduction to a variable chemotherapy with or including PMX.
The clinical response to PMX chemotherapy was evaluated using
RECIST (Response Evaluation Criteria In Solid Tumors) criteria
after 6 months from the end of the treatment by imaging
methods and the patients were divided into responder (CR,
complete or PR, partial responder) and not-responder (NR, with
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FIGURE 1 | Workflow describing the strategy applied in the present study. From left to right: the first panel (violet) presents the design of the PSR, including 28
proteins. Line (A): the MS protein selection process that combines the experimental and bioinformatics steps is presented in 4 frames. The action/software used to
select the DEPs set obtained from the MS data to the final panel is shown. Line (B): each frame contains the proteins of the PSR included in each frame of the
process in line A.
progressive disease) according to RECIST. For proteomic studies,
we considered only biopsies taken before PMX treatment as
those taken after the treatment were collected between 1 and
24 months after the end of the treatment; thus, performing a
post/pre differential proteomic analysis between samples from
the same patient was not feasible due to high differences in
sample collection.
Tissue Samples Preparation
Fifty-two frozen biopsies of ovarian carcinoma stored at −80◦C
belonging to 24 patients were analyzed in order to confirm the
diagnosis of high-grade serous ovarian carcinoma and to define
the percentage of cancer cells in every sample. The biological
specimens consisted of cubes approximately 0.5 cm on each side,
with a weight of around 0.5 g. Each biopsy was cut in halves using
a scalpel. Half was immediately put in dry ice and stored at−80◦C
for the MS analysis. The other piece was immersed in octanol
and was sectioned at 4µm in a cryostat. Haematoxylin/Eosin
(HE) staining was performed on slices obtained and evaluated by
the pathologist (LL). Samples and clinical data information were
obtained from TOC.
For MS analyses, 20 µg of biopsy was chopped through
a scalpel and then quickly weighted to keep it frozen. The
piece was placed in a 2mL microcentrifuge tube containing
1 stainless steel bead (5mm mean diameter) previously
kept on dry ice for at least 15min. The tube was placed
into a TissueLyser LT (Qiagen) adapter, and incubated at
room temperature for 2min. 600 µL of RIPA lysis buffer
[20mM TRIS-HCl, pH 7.5; 150mM NaCl; 1mM Na2EDTA
(Ethylenediaminetetraacetic Acid);1mMEGTA (Ethylene glycol-
bis(β-aminoethyl ether)-N,N,N′,N′-tetra acetic acid tetrasodium
salt]; 1% NP-40 (TergitolTM, Sigma); 1% sodium deoxycholate;
1mM Na3VO4; 1mM PMSF (Phenylmethylsulfonyl fluoride);
Protease inhibitor cocktail (Sigma); Phosphatase Inhibitor
Cocktail 2 and 3 (Sigma Aldrich) were added, then the tissues
were homogenated through the use of TissueLyser LT (Quiagen)
operating at 30Hz for 1 × 2min. Next, the homogenate
was centrifuged at 16,000 r.c.f. for 20min in a precooled
microcentrifuge at 4◦C, the supernatant was collected and the
debris were discarded. Proteins extracted were quantified using
a Bradford assay (Sigma Aldrich).
Protein Digestion via Filter-Aided Sample
Preparation (FASP)
Protein digestion was performed following the protocol reported
in literature (Wis´niewski et al., 2009). 200 µg of a protein extract
of each sample and 200 µl of 8M urea in 0.1M Tris/HCl pH 8.5.
(UA) containing DTT (1,4-Dithiothreitol, Sigma Aldrich) 0.1M
were mixed, and incubated for 30min at 56◦C to reduce thiol
groups. The solution was loaded on aMicrocon YM-30 ultrafilter
(Millipore), and centrifuged at 14,000 r.c.f. for 15min, and
centrifugation was repeated after adding 200µl of UA to the filter
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unit. For the alkylation, 100 µl of a 0.05M iodoacetamide (IAA,
SigmaAldrich) solution inUAwere added and incubated without
mixing for 20min in the dark. Filter units were centrifuged
at 14,000 r.c.f for 10min, washed twice adding 100 µl of UA
to the filter unit, and centrifuged again at 14,000 r.c.f for
15min.
To raise the pH, 100 µl of ABC (Ammonium BiCarbonate)
50mM (Sigma Aldrich) were added to the filter unit and
centrifuged at 14,000 r.c.f. for 10min. This step was repeated
twice. For the digestion, 40 µl of ABC with trypsin (Promega)
were added (enzyme to protein ratio 1:50 w/w) and mixed
at 600 r.p.m. in a thermo-mixer for 1min. The filter units
were incubated in a wet chamber at 37◦C overnight, then they
were transferred to new collection tubes, and centrifuged at
14,000 r.c.f. for 40min. After adding 40 µl ABC, the filter
units were centrifuged again at 14,000 r.c.f. for 10min. Finally,
the pooled extracts were acidified with trifluoroacetic acid and
desalted using solid phase extraction (SPE) cartridges (C18-SD
7 mm/3mL). The peptides were lyophilized using Eppendorf
Concentrator plus (Eppendorf). The samples were subsequently
suspended in 75 µL of an appropriate mobile phase (98%
H2O:2% acetonitrile: 0.1% trifluoroacetic acid) and analyzed on
a Ultra-High Resolution Qq-Time-Of-Flight mass spectrometer
(UHR-QqTOF).
LC MS/MS Label-Free Quantification
Desalted peptide mixtures samples were suspended and
quantificated by NanoDrop assay. Each sample (1 µg) was
analyzed at least three times into a Dionex nRSLC (Rapid
Separation LC nano, Thermo Scientific, Sunnyvale, CA),
coupled online with an Impact HDTM UHR-QqToF (Bruker
Daltonics, Germany). Digests were loaded onto a pre-column
(Dionex, Acclaim PepMap 100 C18, cartridge, 300µm) and
then separated using a 50 cm column (Dionex, ID 0.075mm,
Acclaim PepMap100, C18) at 40◦C using a 360min multistep
gradient at a flow rate of 300 nL/min, as already reported
(Chinello et al., 2015). Eluted peptides were ionized using
nanoBoosterCaptiveSprayTM (Bruker Daltonics) source. MS
acquisition was carried out using data-dependent-acquisition
mode. CID fragmentation was promoted by N2 as collisional
gas. Precursors of preferred charge state ranging from +2 to +5,
with at least 1,575 counts were selected using a fixed cycle time
of 5 s over the 300–2,000 Th window (excluding 1221.5–1,224
m/z) using IDAS (Intensity Dependent Acquisition Speed) and
RT2 (RealTime Re-Think) options. To improve mass accuracy,
in addition to a specific lock mass (1221.9906 m/z) a calibration
segment was performed using 10mM sodium formate cluster
solution before beginning the gradient for each single run (Liu
et al., 2015).
Exported MS2 data from DataAnalysisTM v.4.0 SP4 (Bruker
Daltonics, Germany) were submitted to an in-house Mascot
Server (Matrix Science, UK; v. 2.4.1), through Mascot Daemon.
Database searching was restricted to human Swissprot (accessed
Feb 2017, 553,655 sequences; 198,177,566 residues). Trypsin as
enzyme and carbamidomethyl as fixed modifications were set
in search parameters. One missed cleavage was allowed. Mass
tolerances for all identified hits were set at 20 ppm for the
precursor ions and 0.05Da for the product ions. Automatic decoy
database search was used to estimate the false discovery rate;
peptide-to-spectrum matches were rescored through a built-in
Percolator algorithm. Only proteins with at least one significant
peptide with a score above 13 (p < 0.05) were considered.
Progenesis QI for proteomics v.2.0.5556.29015 (Non-linear
Dynamics, Newcastle, UK) was used as label-free quantification
platform (Raimondo et al., 2015). Briefly, 3 runs for each samples
(technical replicates) after DataAnalysisTM elaboration were
imported as centroided data and were automatically aligned
using a reference run to create a maximal overlay across the
data. The peak picking was set using 0.2min as minimal peak
width, and a default sensitivity. Peptides were identified using
an in-house Mascot search engine as described in the previous
paragraph. Only non-conflicting peptides, not shared between
different proteins, were used for the relative quantification.
Bioinformatics Analysis
The integrated network analysis was conducted with
ProteinQuestTM platform1 and Panther (http://www.pantherdb.
org/) on differentially expressed proteins (DEPs). Panther
compares the proteins list uploaded with a reference proteome
data set (human proteome), in order to identify the biological
process over/under-represented in the uploaded list (Table S5).
It assigns a p-value (applying Bonferroni correction for multiple
testing) to each biological process based on its over/under-
representation in the uploaded list. ProteinQuestTM highlights
any relationship between several type of concepts and biological
items using literature resources and plots the found relationships
as networks between the chosen items. ProteinQuestTM output
has been further checked to be sure that the shown relationships
were based on experimental findings and not only due to the
citation of two proteins in the same article. All plots for the
explorative analysis of abundances, heatmap and clustering have
been realized with the open source software R and Bioconductor
repository, using ggplot2 and Heatplus packages (https://cran.r-
project.org/; https://www.bioconductor.org/).
Western Blot
Seventy micrograms of the biopsies extracts were subsequently
loaded on a polyacrylamide gel. The proteins were reduced with
beta-mercaptoethanol and denaturated by boiling for 10min in
distilled water. The loaded 36 µL were composed of extracted
proteins, RIPA lysis buffer and Laemmli 1X. After SDS-PAGE
with a running buffer [running buffer 1X (Tris 25mM, Glycine
200mM and 0.1% SDS(Sodium dodecyl sulfate)] and a current
of 7–80 Volt for the stacking step and 100V for separating step,
blotting was performed on 0.2µm nitrocellulose membranes
(Hybond-P, Amersham) over night at 200mA. The membranes
were blocked in non-fat dry milk (2 and 5%) in TBS buffer
(Sigma) containing 0.1% Tween-20 at room temperature for 1 h
with agitation.
Primary antibodies were incubated overnight in non-fat dry
milk (2 and 5%) in TBS buffer containing 0.1% Tween-20.
The following antibodies were used: anti-TYSY (clone TS106,
Millipore, 1:250 dilution) in 2% non-fat milk and with 2% milk
1For information about ProteinQuest software, contact Prof. Enrico Bucci at the
following address http://enrico.bucci@resis-srl.com.
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blocked; anti-DRY (sc-74593, Santa Cruz, 1:250 dilution) in 2%
non-fat milk and with 2% milk blocked; anti-PUR2 (12031-
S1, Abnova, 1:500 dilution) in 5% non-fat milk and with 5%
milk blocked. After washing, membranes were incubated with
a horseradish peroxidase-conjugated with a sheep anti-mouse
secondary antibody (AmershamBiosciences, 1:5,000 dilution) for
45min at room temperature in agitation. Membranes remained
in agitation for about 2 h with TBS buffer to wash unbound
antibodies away. The chemiluminescent detection system (ECL
Plus, Amersham) has been spotted above the membranes and
has been left for 5min in the dark at room temperature
before the development. The signal was detected on a X-
ray film (Amersham). Different exposure times were adopted
depending on the protein, ranging from a few seconds to few
hours. The semi-quantitative results of protein expression on
OC tissue lysates before therapy with PMX are reported as
histograms.
For protein concentration normalization purposes, the
membranes were colored with the nonspecific protein dye
Ponceau S. We selected a section of the blot that covered a wide
range of molecular weights in each case, typically approximately
90% or more of the lane length for each protein (Romero-Calvo
et al., 2010). One-way ANOVA analysis was performed with the
open source software R using stats package.
RESULTS
Translational Study
In our studies we identified ovarian cancer tissue samples that
were collected from patients who received platinum drugs as
first line therapy, showed drug resistance and were treated with
PMX as second line therapy. We examined 52 frozen biopsies
(received from the TOC bank) from 24 patients. All samples
were histologically examined and only three samples of high-
grade serous carcinoma collected before PMX treatment were
considered suitable for proteomic studies to compare proteomes
from patients who responded differently to PMX. The samples
information are reported in Table S1 in the Supplementary
Information.
Protein Set of Reference Design
The MS proteomic analysis and selection of the proteins
significantly modulated in the samples is usually performed
through statistical metrics and validated after the final protein
panel compilation. In our analysis, we adopted a Protein Set
of Reference (PSR) as internal validation system. The PSR was
designed by including proteins previously validated in cell-based
experiments and others reported in the literature as relevant to
PMX activity (metadata) (Figures 1A,B and Figure 2) (Taddia,
2015). Identification of a protein subset that characterizes the
activity of folate metabolism targeted Ph.D. thesis. University of
Modena and Reggio Emilia (unpublished data). The PSR was
compiled before starting the MS study and has been used as
an internal validation protein set that was compared with the
actual protein profile obtained during the MS proteomic data
elaboration and was used to define the final panel (Figure 1B).
The PSR includes 28 proteins (Table 1, Figure 2) classified into 2
different groups (Group 1 and Group 2ì-2iv).
First, we included proteins whose expression was modulated
in previous proteomic studies of platinum-resistant cancer cell
FIGURE 2 | ProteinQuestTM network of the proteins belonging to the PSR. The yellow nodes show the drugs used for the search (PMX, cisplatin, and carboplatin)
and the red circles show the proteins used as input. The lines indicate the relationships among the adjacent nodes; the thickness is proportional to the strength of the
relationship. The figure shows both relationship based on biological database information (green and blue arrows) and relationship based on literature information
(black connections) connections. The proteins were grouped as described in Table 1.
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TABLE 1 | Description of PSR and selection criteria.
Selection criteria UniProt Entry name Protein name Gene
Group 1:
Differentially expressed proteins (DEPs) from
studies on OC cell lines (A2780) treated with PMX
HS90A_HUMAN Heat shock protein HSP90-alpha HSP90AA1
TRAP1_HUMAN Heat shock protein 75 kDa, mitochondrial; tumor necrosis
factor (TNF) receptor-associated protein 1
TRAP1
MOS_HUMAN Proto-oncogene serine/threonine-protein kinase mos MOS
PTBP1_HUMAN Polypyrimidine tract-binding protein 1 PTBP1
NDKB_HUMAN Nucleoside diphosphate kinase B NME2
NDKA_HUMAN Nucleoside diphosphate kinase A NME1
Group 2.i:
Folate related proteins and proteins target of PMX
TYSY_HUMAN Thymidylate synthase TYMS
DYR_HUMAN Dihydrofolate reductase DHFR
FOLC_HUMAN dihydrofolate synthase/Folylpolyglutamate synthase,
mitochondrial
FPGS
GGH_HUMAN Gamma-glutamyl hydrolase GGH
PUR2_HUMAN Trifunctional purine biosynthetic protein adenosine-3;
glycinamide ribonucleotide formyltransferase
GART
PUR9_HUMAN Bifunctional purine biosynthesis protein PURH;
5-aminoimidazole-4-carboxamide ribonucleotide
formyltransferase/IMP cyclohydrolase
ATIC
Group 2.ii:
Other proteins connected to PMX
DCK_HUMAN Deoxycytidine kinase\ DCK
S29A1_HUMAN Equilibrative nucleoside transporter 1 SLC29A1
Group 2.iii:
Proteins derived from gene analysis studies on the
response to PMX in platinum-resistant OC patients
ERCC1_HUMAN DNA excision repair protein ERCC-1; excision repair
cross-complementation group 1
ERCC1
FOLR1_HUMAN Folate receptor 1, alpha FOLR1
RFC1_HUMAN Replication factor C subunit 1 RFC1
GSTP1_HUMAN Glutathione S-transferase Pi 1 GSTP1
PCFT_HUMAN Proton-coupled folate transporter SLC46A1
Group 2.iv:
Proteins associated with platinum and multidrug
resistance
MRP1_HUMAN Multidrug resistance-associated protein 1 ABCC1
MDR1_HUMAN Multidrug resistance protein 1 ABCB1
TOP2A_HUMAN DNA topoisomerase II-alpha TOP2A
TOP1_HUMAN DNA topoisomerase I TOP1
CALD1_HUMAN Caldesmon 1 CALD1
PAX8_HUMAN Paired box protein Pax-8 PAX8
MGMT_HUMAN Methylated-DNA–protein-cysteine methyltransferase MGMT
VDAC1_HUMAN Voltage-dependent anion-selective channel protein 1 VDAC1
PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A PPIA
lines (A2780/CP) treated with PMX (Taddia, 2015). Identification
of a protein subset that characterizes the activity of folate
metabolism targeted Ph.D. thesis. University of Modena and
Reggio Emilia (unpublished data) (Table 1: Group 1), namely,
heat-shock protein 90A (HS90A), tumor necrosis factor (TNF)
receptor-associated protein 1 (TRAP1), a proto-oncogene and
serine/threonine kinase (MOS), polypyrimidine tract-binding
protein 1 (PTBP1), nucleotide diphosphate kinase B (NDKB),
and nucleotide diphosphate kinase A (NDKA) (left side,
Figure 2). These proteins have been reported to be involved in
the drug response of OC (Landriscina et al., 2010; Stecklein et al.,
2012; Chu et al., 2013; Genovese et al., 2014).
Other members of the panel were retrieved from a literature-
based analysis performed with ProteinQuestTM (http://www.
proteinquest.com) (Table 1: Group 2). In particular, we searched
for proteins connected to OC, PMX and platinum drugs
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(carboplatin and cisplatin), and gave this as input information
for protein search. These proteins are: (2i) folate-related proteins
and protein targets of PMX: TYSY, dihydrofolate synthase (DYR,
DHFR), folylpolyglutamate synthase (FOLC), gamma-glutamyl
hydrolase (GGH), PUR2, and 5-aminoimidazole-4-carboxamide
ribonucleotide formyltransferase/IMP cyclohydrolase (PUR9)
(2, 12); (2ii) other proteins connected to PMX: deoxycytidine
kinase (DCK) and the equilibrative nucleotide transporter
(S29A1) (Arik and Kulaçoglu, 2011; He et al., 2011; Li et al.,
2012); (2iii) proteins from studies analyzing the response
of genes to PMX in patients with platinum-resistant OC:
excision repair cross-complementation group 1 (ERCC1), folate
receptor 1 (FOLR1), replication factor C subunit 1 (RFC1),
glutathione S-transferase Pi 1 (GSTP1), and proton-coupled
folate transporter (PCFT) (Buqué et al., 2013); and (2iv) proteins
associated with platinum and multidrug resistance: multidrug
resistance-associated protein 1 (MRP1), multidrug resistance 1
(MDR1), topoisomerase II alpha (TOP2A), DNA topoisomerase
I (TOP1), caldesmon 1 (CALD1), paired box protein 8 (PAX8),
Methylated-DNA–protein-cysteine methyltransferase (MGMT),
voltage-dependent anion selective channel 1 protein (VDAC1),
and Peptidyl-prolyl cis-trans isomerase A (PPIA) (Dingemans
et al., 2001; Hegi et al., 2005; Zhang et al., 2008; Auner et al.,
2010; Ferrandina et al., 2010; De Pas et al., 2011; Indran et al.,
2011; Maráz et al., 2011; Bar et al., 2012; Bock et al., 2012;
Curtin, 2012; Melguizo et al., 2012; Mhawech-Fauceglia et al.,
2012; Tyleckova et al., 2012; Johnatty et al., 2013; O’Shannessy
et al., 2013; Kucukgoz Gulec et al., 2014).
Label-Free MS Proteomic Approach for OC
Biopsies
We applied the label-free proteomic approach to identify DEPs,
in the selected biopsies. The MS analysis was performed with an
online pLC coupled Impact HDTM mass spectrometer (Bruker
Daltonics, Germany) and the results were processed using
a robust bioinformatics analysis to identify the connections
between protein profiles and the different response to PMX
treatment.
Of the 2,863 identified proteins, 1,198 different protein IDs
were DEPs in the two responders (complete, CR and partial, PR)
compared with the non-responder one (NR) (Tables S2, S6, S7).
The following filters were applied to elaborate the MS data using
Progenesis QI for proteomics using as selection criteria a fold
change ≥1.5 and ANOVA test p ≤ 0.05 and power ≥0.8.
In Figure 3A a volcano plot shows the 1,198 DEPs in the
responders compared with the NR patient. The p-value is
presented on the Y-axis as –log10 (p-value) and ranges from 1.70
to 8.70 with respect to the maximal expression difference, which
is presented on the X-axis as log10 (Maximal Modulation) and
ranges from −5.45 to −0.17 for the lower expressed proteins
(proteins less expressed in PR/CR than in NR; blue spots, on
the left) and from 0.18 to 6.48 for the higher expressed proteins
(proteins more expressed in PR/CR than in NR; red spots, on the
right). The maximal expression difference is defined as the lower
of the values between the CR/NR and PR/NR abundance ratios
for lower expressed proteins and the higher of the values between
the CR/NR and PR/NR ratios for higher expressed proteins. The
FIGURE 3 | DEPs from the MS study. (A) Volcano plot of the 1,198 proteins; the p-value derived from an ANOVA of the elaborated MS data is reported as –log10 of
the p-value vs. the maximal expression difference of the protein (Maximal Modulation) reported as a log10 value. The maximal expression difference is defined as the
lower of the values between the CR/NR and PR/NR abundance ratios (C/N fold and P/N fold, respectively, in the graphs) for lower expressed proteins and the higher
of the values between the CR/NR and PR/NR ratios (C/N fold and P/N fold, respectively, in the graphs) for higher expressed proteins. The blue and red spots
symbolize the lower and higher expressed proteins, respectively. (B) Scatter plot of 1,198 proteins presented as the log2 value of the P/N fold (ratio between the MS
abundance observed for PR and NR patients) vs. the log2 value of the C/N fold (ratio between the MS abundance observed for CR and NR patients). In both panels:
(i) PRS7, P66A and CD158 proteins are out of scale due to their very large/small C/N and P/N ratio; therefore, they are marked with their coordinates. (ii) Proteins
included in the PSR are indicated with yellow-outlined squares.
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proteins in the high –log10 (p-value) range show the lowest
p-values and therefore represent the statistically most reliable
proteins. Three proteins, coiled-coil domain-containing protein
158 (CD158), proteasome 26S protease regulatory subunit 7
(PRS7) and transcriptional repressor p66-alpha (P66A), were
highly differentially expressed and show a maximal expression
difference that exceeds the range examined and a p-value in the
average range.
In particular, 698 proteins (Figure 3B, top-right quadrant)
were higher expressed in both responders (CR and PR) compared
with the NR patient; 220 proteins were higher expressed in
one of the responders (CR or PR) compared with the NR
patient, but not the other responder. Eight proteins (Figure 3B,
bottom-right quadrant) were higher expressed in the CR patient
compared with the NR patient and were lower expressed in
the PR patient compared with the NR patient. Collectively, all
926 proteins were considered higher expressed proteins. One
hundred thirteen proteins (Figure 3B, bottom-left quadrant)
were lower expressed in both responders (CR and PR) compared
with the NR patient; 120 proteins were lower expressed in one of
the responders (CR or PR) compared with the NR patient, but
not the other responder. Thirty-nine proteins (Figure 3B, top-
left quadrant) were lower expressed in the CR patient compared
with the NR patient, but were higher expressed in the PR patient
compared with the NR patient. Collectively, all 272 proteins were
considered lower expressed proteins.
Twelve out of 28 proteins in the PSR (Table 1, yellow dots
in Figure 3) were detected and quantified by the MS analysis.
Among the 12 proteins, six (TRAP1, PTBP1, PUR2, CALD1,
MGMT, and VDAC1) were higher expressed in both responders
(CR and PR; Figure 3B, top-right quadrant); four proteins
(PPIA, GSTP1, FOLR1, and PUR9) were higher expressed in
the PR patient but were not significantly modulated in the CR
patient (Figure 3B, top quadrants). One protein, NDKB, was
lower expressed in the CR patient and higher expressed in the
PR patient (Figure 3B, top-left quadrant). NDKA was higher
expressed in the PR patient, whereas its level was not significantly
altered in the CR patient (Figure 3B, top-left quadrant).
Biological Process Analysis and Selection
The 1,198 DEPs were processed with PANTHER and
ProteinQuestTM using their annotation to highlight any common
biological processes in which they are involved and to identify
their interconnections. The UniProt Entry Names were used
for the statistical over-representation test in PANTHER (http://
pantherdb.org version 10.0, reference list: Homo sapiens). Eight
hundred forty-nine proteins were classified into 135 biological
processes, 19 of which were statistically significant because of
very relevant or not relevant for the PMX effect (namely over or
under-represented) with a p < 0.05 (Table S3).
The 135 biological processes are listed in the Supplementary
Information (SI; Table S4); we filtered the list of the biological
processes down to 10 members according to their relevance to
OC, evaluated on the basis of literature information (metadata)
and on the basis of the relevance of the processes associated to
PMX drug treatment that contain proteins belonging to the PSR
(Table 1). Four hundred sixty proteins belonging to the selected
processes were considered for further bioinformatic analysis. We
observed that 8 of 12 proteins of the PSRwere also experimentally
detected using MS in our experiments; in fact they were found
among the 460 proteins mentioned above (Table 1). Figure 4
shows a box plot representation of the maximal expression
difference values of the proteins that belong to each of the
19 statistically significantly over/under-represented processes, as
well as the other selected processes; the 10 selected processes are
plotted in yellow.
In particular, we focused our attention on processes
involved in cellular component organization or biogenesis,
protein metabolism, proteolysis, DNA repair, DNA replication,
DNA metabolism, purine nucleobase metabolism, biological
regulation, the cell cycle, and apoptosis.
The biological processes we selected are mainly related to
neoplastic disease (Table 2). The general cancer-related processes
include the genetic control of cell replication (CC) resulting in
massive cell proliferation, and apoptosis (AP), which is essential
for maintaining the physiological balance between cell death
and cell survival. Cellular component organization (CCOB)
includes a number of transcription factors, growth factors and
receptors. Specifically, in epithelial cells such as ovarian epithelial
cells, a distinctive apical-basal polarity is the physiological
morphology, whereas a loss of polarity is frequently assumed to
be a common symptom of cancer progression. Moreover, the
typical neoplastic behavior includes aberrant tissue and cellular
organization and signal transduction. The purine nucleobase
metabolic process (PNMB) involves folate-related proteins and
key proteins associated with the PMX mechanism of action
and proteins required for DNA replication (Dreplic) in cells,
such as cancer cells. The neoplastic process and its regulation
(BR, Drepair) are characterized by mutations in oncogenes
and tumor suppressor genes that cause alterations in multiple
intracellular signaling pathways and affect tumor cell metabolism
(DMP), re-engineering the tumor cell metabolism to allow
enhanced survival and growth. Finally, proteases (P, ProtMP) are
important in multiple processes during malignant progression,
including tumor angiogenesis, invasion and metastasis. Thus,
proteolysis networks that involve different constituents of the
tumor microenvironment and key proteases have been chosen as
important biological processes for future evaluations.
The set of 460 proteins was then enriched with some proteins
considered relevant to our study that were not included by
PANTHER during the selection process; these proteins are part
of the PSR. In particular PTBP1 plays a role in pre-mRNA
splicing and in regulating alternative splicing events. VDAC1
forms a channel through the mitochondrial outer membrane and
the plasma membrane. It is involved in regulating cell volume
and apoptosis. FOLR1 binds folic acid and reduced folates and
mediates the transport of 5-methyltetrahydrofolate and folate
analogs into cells. Moreover, FOLR1 is involved in folic acid
metabolism and is connected to purine nucleobase metabolism.
It is also a known marker of OC, as it is overexpressed in this
cancer type (Kalli et al., 2008). Finally, GSTP1 plays an important
role in detoxification by catalyzing the conjugation of many
hydrophobic and electrophilic compounds into several metabolic
processes.
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FIGURE 4 | Boxplots of the proteins log10(maximal modulation) (maximal expression difference) values (y-axis), associated to significant and/or selected (yellow box)
biological processes (x-axis), sorted by median value. Each biological process is indicated with its acronym (see Table S3). Biological processes that have a p < 0.05
in the Panther’s statistical over-representation test are written in red. Proteins PRS7 and CD158 were labeled with their maximal modulation value due to their very
high expression difference.
TABLE 2 | Selected biological processes description using PANTHER GO-Slim,
and number of proteins.
Biological
process
ID
PANTHER GO-slim biological process N◦ proteins
CCOB cellular component organization or biogenesis 181
ProtMP protein metabolic process 200
Dreplic DNA replication 23
PNMB purine nucleobase metabolic process 13
BR biological regulation 97
P Proteolysis 54
DMP DNA metabolic process 35
CC cell cycle 69
AP apoptotic process 27
Drepair DNA repair 11
Protein Network Analysis and Final Panel
Definition
The ProteinQuestTM platform was queried using the 464 proteins
selected through the biological process analysis as input. The
set of proteins was filtered based on their associations with
OC, cisplatin or carboplatin, and drug resistance; these terms
were used as keywords for protein selection. A panel of 18
proteins was obtained from the selection process (Table 3).
The applied filters are related to the disease and the patient’s
therapeutic features. We decided to integrate the panel of the
18 proteins with some other relevant proteins that include
the main biological targets of PMX, TYSY, DRY, and PUR2,
and 3 DEPs, namely CD158, P66A, PRS7. Among the three
target proteins, thymidylate synthase (TYSY) and dihydrofolate
reductase, DRY, were not detected through MS experiments
because of their low levels, below the limit of detection, while
glycinamide ribonucleoside transferase (PUR2) was detected
in the MS experiments but excluded from the selection; the
3 DEPs showed the greatest change in expression obtained
from the MS experiments (CD158, P66A, PRS7) (Table 3,
Figures 5, 6) and therefore we believed that they are important.
The most relevant biological processes, including the selected
panel, were related to biological regulation, apoptosis, cellular
component organization or biogenesis, protein metabolism,
DNA metabolism, DNA replication, proteolysis, purine
nucleobase metabolism, the cell cycle, cell redox homeostasis,
the glycolytic process and oxidative phosphorylation (Table 3,
Figure 5).
The panel of 24 proteins is presented in Table 3 along with the
main recognized roles of the proteins and the processes in which
they are involved.
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TABLE 3 | Final panel of 24 proteins: function and involvement in cancer mechanisms.
UniProt entry
name
Protein name Gene PANTHER GO-slim biological process CR/NR* PR/NR*
AKT1_HUMAN RAC-alpha serine/threonine-protein kinase AKT1 biological regulation 0.52 0.93
BAX_HUMAN Apoptosis regulator BAX BAX apoptotic process
biological regulation
cellular component organization or biogenesis
3.90 4.76
CYC_HUMAN Cytochrome c CYCS apoptotic process
biological regulation
1.29 1.91
GSHR_HUMAN Glutathione reductase, mitochondrial GSR protein metabolic process 1.58 2.52
GSTP1_HUMAN Glutathione S-transferase Pi 1 GSTP1 PantherDB: unclassified 1.19 2,.18
HXK2_HUMAN Hexokinase-2 HK2 biological regulation 1.17 2.04
IBP3_HUMAN Insulin-like growth factor-binding protein 3 IGFBP3 biological regulation 1.58 1.63
K1C19_HUMAN Keratin, type I cytoskeletal 19 KRT19 cellular component organization or biogenesis 2.27 2.36
PCNA_HUMAN Proliferating cell nuclear antigen PCNA biological regulation
DNA metabolic process
DNA replication
1.81 1.36
PDCD6_HUMAN Programmed cell death protein 6 PDCD6 proteolysis
protein metabolic process
207 2.88
RSSA_HUMAN 40S ribosomal protein SA RPSA cellular component organization or biogenesis
protein metabolic process
0.98 1.65
STAT1_HUMAN Signal transducer and activator of
transcription 1-alpha/beta
STAT1 biological regulation 19.29 11.03
TRAP1_HUMAN Heat shock protein 75 kDa, mitochondrial;
tumor necrosis factor (TNF)
receptor-associated protein 1
TRAP1 protein metabolic process 2.77 1.95
THIO_HUMAN Thioredoxin TXN biological regulation
protein metabolic process
0.59 2.68
ACTB_HUMAN Actin, cytoplasmic 1 ACTB cell cycle
cellular component organization or biogenesis
12.74 26.32
AIFM1_HUMAN Apoptosis-inducing factor 1, mitochondrial AIFM1 protein metabolic process 4.20 2.38
PLMN_HUMAN Plasminogen PLG proteolysis
protein metabolic process
2.33 0.82
TF65_HUMAN Transcription factor p65 RELA biological regulation 0.11 1.35
TYSY_HUMAN Thymidylate synthase TYMS PantherDB: unclassified — —
DRY_HUMAN Dihydrofolate reductase DHFR PantherDB: unclassified — —
PUR2_HUMAN Trifunctional purine biosynthetic protein
adenosine-3; glycinamide ribonucleotide
formyltransferase
GART purine nucleobase metabolic process 2.07 2.34
CD158_HUMAN Coiled-coil domain-containing protein 158 CCDC158 cell cycle <3.6 × 10−6 >1.1 × 10−3
P66A_HUMAN Transcriptional repressor p66-alpha GATAD2A PantherDB: unclassified >1.4 × 106 >0.7 × 106
PRS7_HUMAN Proteasome 26S protease regulatory
subunit 7
PSMC2 cellular component organization or biogenesis
proteolysis
protein metabolic process
>1.5 × 106 >3.0 × 106
*Abundance ratio; CR, complete responder; PR, partial responder; NR, non-responder.
To highlight the metabolic connections of the selected 24
protein panel, we interrogated ProteinQuestTM with the proteins
as input data and obtained the network reported in Figure 5.
Figure 5 illustrates the network representing the metabolic
connection of the 24 selected proteins, which provide a functional
picture (biological processes) of the integration of the selected
protein features, thereby proposing a predictive model for drug
responses. To rationally address the functional role of the 24
panel network we thoroughly examined the functions of the
selected proteins and their involvement in cancer mechanisms
and drug responses using literature information.
With the aim of understanding if the selected proteins were
significantly differently expressed in CR and PR with respect to
NR, we used the heat map clustering method.
Figure 6A shows the heat-map of the logarithmic values of
the MS abundances of 22 proteins in the final panel. The patient
clustering (Euclidean distance, dendrogram cut = 6.0, complete
linkage clustering) shows a similarity between the CR and PR
patients compared with the NR patient. In Figure 6B, the MS
abundance ratios (CR/NR and PR/NR) for the 22 proteins in the
final panel are represented as bar codes. Thirteen of 22 proteins
form a consensus bar code protein change that characterizes the
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FIGURE 5 | ProteinQuestTM network of the final proteins panel. The red circles show the proteins used as the input. The lines indicate the relationships among
adjacent nodes; the thickness is proportional to the strength of the relationship. The figure shows both relationships based on biological database information (green
and blue arrows) and relationship based on literature information (black connections) connections Proteins were grouped based on the biological process in which
they are involved. The blue islet represents the proteins involved in the apoptotic process, the red islet indicates proteins implicated in biological regulation, and the
orange islet shows proteins related to DNA replication and metabolic processes. The violet islet represents cell cycle proteins, the dark blue islet indicates proteins
involved in the cellular component organization or biogenesis biological process, and the gray islet shows the proteins involved in metabolic processes. The proteins
involved in proteolysis are highlighted in light blue, and the proteins shown in brown are involved in oxidative phosphorylation. The light-green islet represents proteins
related to cellular redox homeostasis and the dark green islet indicates proteins involved in the glycolytic biological process. Additionally, TYSY (TYMS), DYR (DHFR),
and PUR2 (GART), which are PMX protein targets, are highlighted in the light blue islet, and the rose islet shows the highly different expressed proteins (see Table 3).
responders: PDCD6, GSHR, TRAP1, STAT1, PUR2, BAX, IBP3,
K1C19, AIFM1, ACTB, CD158, PRS7, and P66A.
From the heat-map clustering analysis the CR and PR show a
different protein expression with respect to NR thus supporting
the concept that the 24 protein panel is predictive for PMX
response in the present study.
Western Blot Studies
Lysates were obtained from the three selected biopsies and
were subjected to a western blot (WB) analysis of the known
PMX protein targets (TYSY, DYR, and PUR2) (Figure 7). The
immunoblot technique allowed us to identify low-abundance
proteins, such as proteins in the folate pathway, thus overcoming
the concentration limits imposed by the MS analysis. In our case,
both TYSY and DRY were not detected by MS, but literature
data show that they are modulated by PMX. The CR patient
showed lower expression of TYSY and DRY than the PR and NR
patients; intermediate levels of these proteins were detected in the
PR patient, and higher levels were observed in the NR patient.
These results are consistent with the results reported by Huang.
et al., who showed that the expression of the TYSY protein is
associated with the cancer prognosis (Huang et al., 2015). PUR2
is the only protein that was related to PMX activity and detected
with MS. Therefore, we performed the WB assay to validate the
MS finding. PUR2 expression varies to an extent similar to the
results obtained in the MS experiments.
DISCUSSION
In platinum-resistant OC tissues, a protein profile associated with
the PMX response was related to a consistent set of proteins
using a combined bioinformatics/MS proteomic approach. This
panel includes proteins related to the PMX mechanism of
action and was examined using an MS proteomic analysis of
tissue samples from the patients. Due to difficulties in finding
tissue samples with the wanted characteristics we could only
select three patients who received chemotherapy and platinum
drug and were treated further with PMX in second or third
line therapy. The high heterogeneity of the tissue sample set
allowed the selection of three pre-treatment tissue samples. The
proteomic analyses highlight a panel of proteins whose levels
were significantly different in samples obtained from patients
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FIGURE 6 | Representations of the final selected protein panel obtained from
the MS analysis. (A) Heat-map of the logarithmic values of the MS
abundances of 22 proteins in the final panel. The reported dendrogram was
built based on the dissimilarity matrix using Euclidean distances and the
average linkage method. For the dendrogram, a cut-off of 3 was used for the
proteins, and a cut-off of 6 was used for the patients. NR, non-responder; CR,
complete responder; PR, partial responder. In the heatmap representation the
abundance values is in logarithmic scale in base 10, thus differences between
CR, PR, and NR are clearly visible only if a difference of at least one order of
magnitude in the protein abundance values exists. (B) Bar code representation
of the MS abundance ratios (CR/NR and PR/NR) of the 22 proteins in the final
panel. Thick bars represent higher expressed proteins, whereas thin bars
represent lower expressed proteins. The bar code representation of the ratios
of the abundance values (CR/NR and PR/NR); thus differences between CR,
PR, and NR are clearly visible when the ratio are higher than 1.5 or lower than
0.66.
before they received treatment. The global interpretation of the
MS data was performed through bioinformatics analysis and was
assisted by a PSR designed ad hoc.
We identified 24 proteins (Table 3) that might be used as a
protein signature to guide the choice of treatment with PMX
FIGURE 7 | Semi-quantitative analysis of proteins expression in OC tissue
lysates before therapy with PMX. Histograms represent the densitometric
values for each protein normalized to the respective Ponceau S-stained gel.
Values are means±s.e. * p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
by ANOVA test.
when standard first-line treatments have failed. The limitation of
this study is the availability of only one sample for each patient
category (CR, PR, NR), therefore it can be considered as a proof
of concept study. Future evaluations will be directed toward
the retrospective validation of the panel in a higher number of
patient’s samples.
Each of the identified proteins is also studied in several cancers
other thanOC. However, the set of 24 proteins and their variation
in patients CR, PR, and NR, can be considered as a protein
signature specific for the OC sub-population of this study, as
reported in the bar code frame in Figure 6. The heat-map of the
24 proteins provides the quantitative outcomes that characterize
the NR patient compared with the PR and CR patients. The
protein levels observed in the NR patient significantly differ from
that in the PR and CR patients. WB analyses of PMX target
proteins showed that TYSY and DYR levels differ in a manner
consistent with the literature, whereas PUR2 varies in a manner
consistent with the data from the MS experiments. Neither TYSY
nor DYR were detected in the MS experiments, but their levels
were higher in the NR with respect to the CR and PR, in
the WB.
We have described the biological role of the proteins included
in the final set, in a cancer disease status and found a rationale
that may explain their modulation in MS experiments.
The insulin-like growth factor (IGF) binding protein 3 (IBP3)
belongs to a family of six proteins that transport IGF-I and
IGF-II in the blood circulation and regulate their access to the
potentially oncogenic IGF-I receptor (IGF1R) (Baxter, 2014).
Several studies describe an inhibitory effect of IBPs on IGF-
dependent tumor growth and drug resistance. IBP3-mediated
methylation is associated with disease progression and death
in patients with OC, suggesting that a reduction in the IBP3
levels may be a useful prognostic marker of disease progression
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and death (Wiley et al., 2006). According to several basic
and translational studies (Denduluri et al., 2015), IGF pathway
modulators might have promising effects when used to treat
various malignancies. The IGF signaling pathway appears to
play an important role in the drug resistance of OC. In A2780
ovarian carcinoma cells, drug resistance to either cisplatin
or the combination of cisplatin and Taxol is correlated with
the upregulation of IGF-1R expression. Furthermore, primary
tumors collected from patients after 3/4 cycles of carboplatin-
Taxol treatment also exhibit increased IGF-1R expression
(Singh et al., 2014).
The expression of IBP3, keratin, type 1 cytoskeletal 19
(K1C19), and other genes is decreased in platinum-resistant
ovarian carcinoma cell lines that were derived from the parental
line by exposing the cells to increasing concentrations of
cisplatin. The altered expression of these proteins suggests that
they are involved in the process of drug resistance (Macleod,
2005).
Thioredoxin reductases (THIO) and glutathione reductase
(GSHR) are fundamental enzymes that participate in the defense
against oxidative damage related to oxygen metabolism. The
importance of the redox status in the drug resistance of many
types of cancers is well known. Recent studies have reported
a critical role for oxidative stress in the development of drug
resistance in epithelial OC (EOC). Two OC cell lines (MDAH-
2774 and SKOV-3) and their chemo-resistant counterparts have
been compared and the results showed a significant decrease in
the levels of the GSHR mRNA levels and GSHR activity in both
cisplatin-resistant cell lines, suggesting that the development
of drug resistance might be caused by a pro-oxidant state in
these cells (Belotte et al., 2014). Although tumor cells have
long been considered defective in mitochondrial respiration and
primarily depend on glycolytic metabolism (the Warburg effect),
recent observations provide contrasting evidence showing that
melanoma cells and breast cancer cells are critically dependent
on oxidative phosphorylation (OXPHOS) rather than glycolysis
(Haq et al., 2013; LeBleu et al., 2014).
Notably, the most aggressive OC cell lines show a marked
dependence on glutamine rather than glucose (Yang et al.,
2014). In addition, cancer stem cells obtained from patients
with EOC preferentially utilize OXPHOS and resist glucose
deprivation (Pastò et al., 2014). Recently, TRAP1 has been shown
to play important roles in regulating oxidative metabolism in
OC cells. A strict correlation between low TRAP1 expression
and oxidative metabolism in OC cells is responsible for the
progression of cancer and the response to platinum-based
therapies through the activation of an inflammatory program
(Matassa et al., 2016). The same study revealed that the
multidrug resistance proteins transporter 1, ATP binding cassette
subfamily B member (TAP1) and MDR1, which belong to the
MDR subfamily, are key mediators of metabolism-driven and
inflammation-induced drug resistance. Hexokinase-2 (HK2), the
first rate-limiting enzyme in the glycolytic pathway, is known
to be up-regulated in many cancers, and its overexpression
correlates with short progression-free survival, which may
be associated with chemoresistance in EOC (Suh et al.,
2014). HK2 inhibits mitochondrial apoptosis through direct
insertion in the mitochondrial outer membrane (Mathupala
et al., 2006) and by inhibiting cytochrome c (CYC) release
(Pastorino et al., 2002).
Based on recent evidence, deregulation of the pro- and anti-
apoptotic pathways is a key factor involved in the onset and
maintenance of chemoresistance in OC (Fraser et al., 2003).
Among the regulators of apoptosis, BAX (a member of the
Bcl-2 gene family) strongly influences the response of OC
to cisplatin-based chemotherapy. The BAX expression level
displays a predictive value in patients with OC who are treated
with platinum-based chemotherapy, and appears to be the
strongest prognostic indicator of disease-free survival (DFS) in
the TP53(+) patient group (Kupryjanczyk et al., 2003). The
expression level of programmed cell death 6 (PDCD6), a recently
discovered pro-apoptotic protein, is down-regulated in cancer
cell lines and OC tissues compared with that in normal cells and
tissues (Park et al., 2012). The results of this study highlight the
key roles of PDCD6 and cisplatin in tumorigenesis. The ectopic
expression of PDCD6 in the SKOV-3 OC cell line combined with
cisplatin treatment is more effective in suppressing cell growth
than the drug treatment alone. Furthermore, the authors provide
evidence that PDCD6 mediates the pro-apoptotic activity of
cisplatin by down-regulating the nuclear factor-κB (NF-κB)
pathway.
The transcription factor p65 (TF65) is a REL-associated
protein involved in NF-κB heterodimer formation, nuclear
translocation and activation. As shown in a recent in vitro
analysis of EOC cell lines, epidermal growth factor receptor
(EGFR) activates NF-kB transcription, which in turn induces
the secretion of interleukin-6 (IL-6) and plasminogen activator
inhibitor (PAI-1). PAI-1 inhibits urokinase plasminogen
activator (UPA), an enzyme responsible for the cleavage of
plasminogen (PLMN) to produce plasmin. In the same study,
the authors proposed that EGFR, NF-kB, IL-6, and PAI-1 may be
novel prognostic markers and might have a significant impact
on therapy for a particular subset of patients with EOC (Alberti
et al., 2012).
The signaling cascade that involves phosphoinositide 3-kinase
(PI3K), AKT, and mammalian target of rapamycin (mTOR)
is the most frequently altered pathway in human cancer and
controls many of the processes that play important roles in
mediating cancer onset and development (cell survival, mobility,
metabolism, the cell cycle, angiogenesis, genomic instability
and chemoresistance) (Fruman and Rommel, 2014). OC often
exhibits alterations in one or more components of this signaling
pathway, including the mutation and/or amplification of the
oncogenes AKT1 and AKT2 (Cheng et al., 1992; Carpten et al.,
2007). Notably, a phase I trial has been conducted using a
combination of perifosine, an AKT inhibitor, and docetaxel in
patients with recurrent OC. The treatment was more effective
when the PI3K/AKT pathway was activated (Fu et al., 2012).
Although activation of the PI3K/AKT pathway appears to be
required for a better response to treatment, Hanrahan et al.
(Hanrahan et al., 2012) reported that this pathway is necessary,
but not sufficient, to confer sensitivity to the AKT-selective
inhibitor. Cells that contain RAS pathway alterations or a loss
of retinoblastoma-associated protein (RB1) are resistant to AKT
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inhibition, regardless of whether the PI3K/AKT pathway is
activated.
Furthermore, cisplatin-induced apoptosis proceeds, at least
in part, via a caspase-independent mechanism that involves
apoptosis-inducing factor 1 (AIFM1), and in OC, AKT activation
confers resistance to cisplatin-induced apoptosis by blocking this
pathway (Yang et al., 2008).
Cisplatin-resistant cells often exhibit decreased uptake of
cisplatin in combination with decreased endocytosis. Two major
carboplatin-binding proteins, filamin and beta-actin (ACTB),
are implicated in this process. Decreased expression of these
two proteins was observed in two different human cisplatin-
resistant cell lines (KB-CP20 and 7404-CP20) compared with
the expression in their parental cell lines (KB-3-1 and BEL-
7404) (Dasari and Tchounwou, 2014). Furthermore, the ACTB
protein was up-regulated in patients with advanced-stage OC
who responded to carboplatin and paclitaxel chemotherapy
compared with non-responders (Sehrawat et al., 2016).
Notably, the 40S ribosomal protein SA (RSSA) is up-regulated
in A2780 cisplatin-resistant cell lines compared with the levels
observed in the parental A2780 cell line. This ribosomal
protein also functions as a cell surface receptor for laminin.
Laminin has been implicated in a wide variety of biological
processes, including cell adhesion, differentiation, migration,
metastasis and drug resistance. Thus, the overexpression of
RSSA, which has been observed in many cancers, suggests that
it has potential roles in tumor progression and drug resistance
(Al-Eisawi et al., 2016).
Finally, we identified other relevant proteins that are
potentially involved in the drug resistance of OC, namely,
proliferating cell nuclear antigen (PCNA), signal transducer and
activator of transcription 1-alpha/beta (STAT1), and GSTP1. The
mechanisms by which they exert their action are diverse, ranging
from cell cycle control, DNA methylation, DNA replication and
repair (PCNA) (Hartmann et al., 1992) to drug metabolism
(GSTP1). GSTP1 has an important role in cisplatin and
carboplatin metabolism in OC cells, and alterations in GSTP1
expression may therefore influence the response of patients with
OC to chemotherapy (platinum-based) (Sawers et al., 2014).
Interestingly, a significant increase in apoptosis after platinum
treatment was observed following the knockdown of STAT1 in
resistant OC cells (Stronach et al., 2011).
Three proteins that were highly deregulated in the CR patient
compared with the NR patient are 26S protease regulatory
subunit 7 (PRS7), transcriptional repressor p66-alpha (P66A) and
coiled-coil domain-containing protein 158 (CD158). PRS7 is a
component of the 26S proteasome that is involved in protein
degradation and is required for the maintenance of protein
homeostasis by removing misfolded or damaged proteins.
Notably, this system has well-known roles in regulating the
sensitivity of OC to treatment (Bazzaro et al., 2006). P66A
is a structural component of the nucleosome remodeling and
deacetylase (NuRD) complex, which regulates gene expression at
the chromatin level. Based on emerging evidence, modifications
in NuRD subunits modulate their function within the complex,
potentially providing additional drug targets (Lai and Wade,
2011).
Overall the present discovery proteomic study shows a
behavior that is consistent with the response to PMX treatment.
We previously performed a study on cancer cells using
an investigational peptide candidate to evaluate the protein
signature associated with its mechanism of action. In those
experiments, we used a knowledge-based approach combined
with MS proteomics and bioinformatics. In the present work,
we have transferred a similar approach to the study of
tissue samples with the aim of identifying a protein set by
implementing an alternative experimental design. The two
studies show different applications of the proteomic studies that
encompass the experimental design, sample management and
global data interpretation. However, they both demonstrate how
the combination of different approaches with a metadata-based
protein selection drive to the final protein set.
The relevant methodological aspect of the present study is the
design of a PSR as a tool for protein selection. The final panel
identified represents a proof of concept that requires validation
in a higher number of samples to evaluate its capacity to predict
weather patients with OC who have received multiple treatments
and are resistant to platinum drugs will respond to PMX.
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